Total global spending on prescription drugs could reach $1.4 trillion by 2020, according to a new report.
The ‘Global Medicines Use in 2020’ report from IMS Institute for Healthcare Informatics says that increased patient access to medicines across the world and high-priced drugs for chronic diseases will result in a compound annual growth rate of four to seven percent over the next five years.
It adds that the average cost per dose will be 30 cents by 2020, and 4.5 trillion doses of medicine will be dispensed, an increase of 24 percent from 2015.
The report also predicts that around 255 new drugs will come to market over that time, about a third of which will be for the treatment of cancer. The cost of these new treatments will be partially offset by increasing patent expirations which could reduce spending on branded medicines by $178 billion.
The total spend on drugs this year is estimated to be about $1.07 trillion.
“We are now getting much more value for every dollar we spend because we can get decades’ worth of innovation, most of it incredibly cheaply because generics are widely available,” commented Michael Kleinrock, research director for the IMS Institute.
By George Underwood
Source: Pharma Times
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.